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ORIGINAL ARTICLE
Is Anti–Citrullinated Protein Antibody–Positive
Rheumatoid Arthritis Still a More Severe Disease
Than Anti–Citrullinated Protein Antibody–
Negative Rheumatoid Arthritis? A Longitudinal
Cohort Study in Rheumatoid Arthritis Patients
Diagnosed From 2000 Onward
ALEID C. BOER,1 ANNELIES BOONEN,2 AND ANNETTE H. M. VAN DER HELM VAN MIL3
Objective. Because of its association with joint destruction, anti–citrullinated protein antibody (ACPA)–positive rheuma-
toid arthritis (RA) is considered to be more severe than ACPA-negative RA. Clinically relevant joint destruction is now
infrequent thanks to adequate disease suppression. According to patients, important outcomes are pain, fatigue, and inde-
pendence. We evaluated whether ACPA-positive RA patients diagnosed during or after 2000 have more severe self-reported
limitations and impairments, including restrictions at work, than ACPA-negative RA patients.
Methods. A total of 492 ACPA-positive and 450 ACPA-negative RA patients who fulfilled the 2010 criteria and were included in
the Leiden Early Arthritis Clinic cohort during or after 2000 were compared for self-reported pain, fatigue, disease activity, gen-
eral well-being (measured by numerical rating scales), physical function (measured by the Health Assessment Questionnaire),
and work restrictions, including absenteeism at baseline and during the 4-year followup. Linear mixed models were used.
Results. At disease presentation, ACPA-negative patients had more severe pain, fatigue, self-reported disease activity
scores, and functional disability (P < 0.05), although absolute differences were small. During followup, ACPA-negative
patients remained somewhat more fatigued (P = 0.002), whereas other patient-reported impairments and limitations were
similar. Thirty-eight percent of ACPA-negative and 48% of ACPA-positive patients reported absenteeism (P = 0.30), with
median 4 days missed in both groups in the last 3 months. Also, restrictions at work among employed patients and restric-
tions with household work were not statistically different at baseline and during followup.
Conclusion. In current rheumatology practice, ACPA-positive RA is not more severe than ACPA-negative RA in terms of
patients’ relevant outcomes, including physical functioning and restrictions at work. This implies that efforts to further
improve the disease course should be proportional to both disease subsets.
INTRODUCTION
Anti–citrullinated protein antibody (ACPA)–positive and
ACPA-negative rheumatoid arthritis (RA) patients are con-
sidered as having different disease entities with differences
in etiopathology, as both subsets have differences in genetic
and environmental risk factors (1). ACPA-positive RA has
always been considered as a more severe subset of RA, as
the presence of ACPA is associated with more severe joint
destruction and a higher mortality rate (2–4).
During the last decade treatment strategies have im-
proved, and earlier treatment initiation and treat-to-target
approaches have resulted in better disease outcomes (5).
Especially from the year 2000 onward, early treatment with
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methotrexate (MTX) has become key and, at present, clini-
cally relevant joint destruction has become infrequent (6–
10). In addition, RA patients no longer have an evidently
increased mortality rate (11–13). Therefore, these tradi-
tional outcomes of RA have become less important. This
leads to the consideration of what should be the current
essential disease outcomes.
A recent study emphasized determining these outcomes,
and according to patients, the important outcomes are pain,
fatigue, and independence (14). Independence strongly
relates to physical functioning and the ability to perform
one’s tasks at home and at work (15). It is still unknown if
ACPA-positive patients in current rheumatology practice
have a worse disease than ACPA-negative RA patients, as
evaluated with the abovementioned patient-reported out-
comes (PROs). Therefore, this study assessed, in RA patients
who were diagnosed from 2000 onward and were treated
with up-to-date treatment strategies, whether ACPA-posi-
tive patients have more severe PROs, including functional
disability and work restrictions, than ACPA-negative RA
patients.
PATIENTS AND METHODS
Longitudinal cohort. Patients were included in the
Leiden Early Arthritis Clinic (EAC) cohort, a population-
based inception cohort in The Netherlands that started in
1993. Inclusion required the presence of arthritis confirmed
at physical examination and symptom duration <2 years.
Baseline visit was at first presentation of arthritis at the out-
patient clinic. Followup visits were performed yearly with
questionnaires, 66 swollen (SJC66) and 68 tender joint counts
(TJC68), and laboratory investigations (including C-reactive
protein [CRP] level, immunoglobulin M– rheumatoid factor
[RF; positive if ≥3.5 IU/ml] and ACPA [anti–cyclic
citrullinated peptide (anti-CCP2), Eurodiagnostica, positive
if ≥25 U/ml; from 2009 EliA CCP, Phadia, positive if ≥7 U/
ml], as described in detail elsewhere [16]). For the present
study, RA patients included in the Leiden EAC cohort during
or after 2000 were analyzed. Patients were treated according
to routine care. According to local and national protocols,
patients were treated initially with MTX; in case of failure a
second conventional disease-modifying antirheumatic drug
(DMARD) was started or added, and in case of subsequent
failure a biologic DMARD was allowed. The strategy of
treatment adjustment changed over time, as in our hospital
Disease Activity Score (DAS)–steered treatment adjustments
became standard as of 2005 (17,18).
To measure experienced pain, fatigue, disease activity,
and general well-being, patients were asked by trained re-
search nurses to indicate on single-item numerical rating
scales (NRS), ranging from 0 (no symptoms) to 10 (extreme
symptoms), the grade that best reflected how they felt
affected by arthritis during the last 24 hours. To measure lim-
itations in physical functioning, the multi-item Health
Assessment Questionnaire (HAQ), expressed as a disability
index (DI) from 0 (no disability) to 3 (severe disability), was
used. A questionnaire on work ability was added to the study
protocol in 2010. It contained questions from 1) the RA-spe-
cific Work Productivity Survey, addressing work status and
type of work; 2) the Work Productivity and Activity Impair-
ment Rheumatoid Arthritis questionnaire, assessing influ-
ence of disease on productivity at a paid job (presenteeism)
or during nonpaid work in the past 7 days, ranging from 0
(no restrictions) to 10 (severe restrictions); and 3) additional
questions on the number of days patients had worked with
these restrictions in the past 7 days, as well as work days
absent in the past 3 months (see Supplementary Table 1,
available on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23497/abstract).
Among employed patients at baseline, we analyzed
absenteeism and the number of patients that reported absen-
teeism; we also analyzed presenteeism (level of restrictions
at work) and the number of days employed patients had
worked with restrictions in the last week due to arthritis, as
well as restrictions with household activities for all patients.
Data were gathered at baseline and at the yearly followup
visits. Written informed consent was obtained from all
patients. The study was approved by the local medical
ethics committee.
Patient selection. From all early arthritis patients in-
cluded between 1993 and 2016 (n = 3,722), 2,615 were
included during or after 2000; of these, 982 fulfilled the
2010 classification criteria for RA at baseline (19) (see
Supplementary Figure 1, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/10.
1002/acr.23497/abstract).
RA patients with missing ACPA status were excluded (n =
40); they did not differ in age, sex, SJC66, CRP level, RF posi-
tivity, or symptom duration from patients with available
ACPA data (see Supplementary Table 2, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23497/abstract). In total, 450 ACPA-
negative and 492 ACPA-positive patients were studied. To
evaluate whether the choice of classification criteria affected
the results, analyses were repeated with RA defined as ful-
filling the 1987 criteria (20). Of the 2,615 patients included
from 2000 onward, 563 fulfilled the 1987 criteria at baseline
(225 ACPA-negative patients, 338 ACPA-positive patients).
A portion of the patients that fulfilled the 1987 criteria did
not fulfill the 2010 criteria and vice versa.
Since the introduction of the questionnaire on work abil-
ity in 2010, 130 ACPA-negative and 152 ACPA-positive RA
Significance & Innovations
• Anti–citrullinated protein antibody (ACPA)–posi-
tive rheumatoid arthritis (RA) is known for its more
severe disease course, compared to ACPA-negative
RA.
• With current treatment strategies, both disease sub-
sets are equally severe in terms of patient-reported
outcomes, including physical functioning and re-
strictions at work.
• This implies that further efforts to improve the
disease course should be proportional to ACPA-
positive and ACPA-negative RA.
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patients fulfilling the 2010 criteria were included (see Sup-
plementary Figure 1, available on the Arthritis Care &
Research web site at http://onlinelibrary.wiley.com/doi/10.
1002/acr.23497/abstract). Of these 282 patients, 24 ACPA-
negative and 36 ACPA-positive patients did not fill in the
work ability questionnaire at baseline. These 60 patients did
not differ in age, sex, symptom duration, SJC66, CRP level,
or RF positivity from those who did complete the work abil-
ity questionnaire (see Supplementary Table 3, available on
the Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23497/abstract). The addition of
this questionnaire later in the study does not cause a bias, as
missingness is completely at random.
Statistical analyses. We presented median levels and
corresponding interquartile ranges. Baseline data were
analyzed with a t-test, the Mann-Whitney U test, and chi-
square test as appropriate.
For longitudinal analyses between ACPA-negative and
ACPA-positive patients, linear mixed models were used.
Although PROs were non-normally distributed, the residu-
als were normally distributed and thus fulfilled the require-
ment for linear mixed models. Patients were censored after
4 years of followup because the number of patients with
followup longer than this period decreased. No random
effects were added to the model (21,22). This model has the
advantage that all patient information, including those who
had missing data of PROs, was used, as it assumes that
missing outcomes can be estimated using available
measurements. Also, to prevent bias due to selective drop-
out of patients, we did not apply a minimum followup
duration for inclusion in the analyses. To determine the
best-fitting covariance matrix, the matrices available in
SPSS were considered. Akaike information criterion was
used to measure the goodness-of-fit, as this was best for the
compound symmetry matrix. We obtained estimates of
the main effect of ACPAs. Because the target variables are
known to vary with age and sex, adjustments were made in
all longitudinal analyses. For PROs of impairments and
limitations, adjustments for the year of inclusion were also
made (23–25). In analyses, median values of estimated coef-
ficients of the longitudinal analyses are shown. IBM SPSS,
version 23, was used, and values less than 0.05 were con-
sidered significant.
Sensitivity analyses. In sensitivity analyses, it was first
evaluated whether results would be different when ACPA-
negative and RF-negative patients were compared to patients
with positive ACPA and/or RF, as part of the ACPA-negative
patients were RF positive. Second, analyses were repeated
in patients that were included during or after 2005. This was
done as this study aimed to evaluate patients who were
treated according to current treatment strategies. Although
an early start of MTX was common from 2000 onward, DAS-
steered treatment adjustments became fully integrated in
daily practice in our hospital from 2005 onward (18).
Finally, as a reference showing that patients treated accord-
ing to up-to-date treatment strategies were different from
patients who were treated in the past, we performed similar
analyses for patients who were included in the EAC between
1993 and 1999. In this era, DMARDs were initiated with
delay, and/or mild DMARDs (such as hydroxychloroquine)
were started as initial therapy, as described elsewhere (5).
RESULTS
Patient characteristics. Table 1 presents baseline char-
acteristics of included RA patients (fulfilling the 2010
criteria). ACPA-negative patients were older (mean age 63
versus 54 years; P < 0.001), had more swollen joints than
ACPA-positive patients (median 9 versus 5; P < 0.001),
more tender joints (median 16 versus 10; P < 0.001), and a
shorter disease duration (median 103 versus 144 days; P <
0.001). Over time a similar proportion (70–80%) of patients
Table 1. Baseline characteristics of RA patients (fulfilling 2010 criteria) for analyses on patient-reported impairments and
limitations, and work restrictions*
Impairments and limitations Work restrictions
ACPA-negative
(n = 450)†
ACPA-positive
(n = 492)‡ P
ACPA-negative
(n = 130)§
ACPA-positive
(n = 152)¶ P
Impairments and limitations
Age, mean  SD years 60  16 54  14 < 0.001 59  16 54  14 0.009
Female, no. (%) 295 (66) 333 (68) 0.49 90 (69) 99 (65) 0.47
TJC68, median (IQR) 16 (10–24) 10 (5–17) < 0.001 13 (8–21) 8 (4–12) < 0.001
SJC66, median (IQR) 9 (4–14) 5 (3–10) < 0.001 7 (3–12) 5 (2–8) 0.005
CRP (mg/liter), median (IQR) 12 (3–32) 11 (4–24) 0.40 11 (3–32) 8 (3–18) 0.12
RF positive, no. (%) 154 (34) 431 (88) < 0.001 58 (45) 129 (85) < 0.001
Symptom duration, median
(IQR) days
103 (58–194) 144 (72–294) < 0.001 94 (46–210) 121 (68–280) 0.035
* P values for age obtained with t-test, chi-square test for dichotomous variables, and Mann-Whitney U test for the other continuous variables. RA =
rheumatoid arthritis; ACPA = anti–citrullinated peptide antibody; TJC = tender joint count (68 joints assessed); IQR = interquartile range; SJC = swollen
joint count (66 joints assessed); CRP = C-reactive protein; RF = rheumatoid factor.
† TJC was missing in 2 patients, SJC in 1 patient, CRP level in 9 patients, RF in 1 patient, and symptom duration in 12 patients.
‡ TJC was missing in 1 patient, CRP level in 6 patients, RF in 3 patients, and symptom duration in 27 patients.
§ Symptom duration was missing in 1 patient, and SJC in 1 patient.
¶ RF was missing in 1 patient, CRP level in 1 patient, and symptom duration in 1 patient.
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achieved DAS-remission (44 joints assessed, DAS < 2.4)
(Figure 1), indicating that despite differences in charac-
teristics between both groups the disease activity was
equally suppressed in both groups.
Patient-reported impairments and limitations at base-
line. ACPA-negative patients reported statistically signifi-
cant more pain than ACPA-positive patients (median 5.8
versus 5.2; P = 0.045), more severe fatigue (median 5.5 versus
5.0; P = 0.003), more severe disease activity (median 6.1
versus 5.6; P = 0.006), and more functional disability (median
1.0 versus 0.9; P = 0.001), although absolute differences were
small (Figure 2A). General well-being was equal for both
groups of patients (median 4.3 versus 4.0; P = 0.25).
As, due to the composition of the 2010 criteria, ACPA-
negative patients can only fulfill the criteria in the case of
>10 involved joints, and as ACPA-negative patients indeed
had more swollen joints, we hypothesized that the patient
selection by the criteria used might explain the higher
PROs in ACPA-negative patients. Therefore analyses were
repeated in the RA patients fulfilling the 1987 criteria. Base-
line characteristics are shown in Supplementary Table 4,
available on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23497/abstract. Here,
no significant differences were observed between ACPA-
negative and ACPA-positive RA patients (Figure 2B).
Course of patient-reported impairments and limitations
during 4 years of disease. The 450 ACPA-negative and 492
ACPA-positive RA patients (fulfilling 2010 criteria) were
studied during 4 years of followup, as shown in Figure 3,
which shows the predicted values adjusted for age, sex, and
year of inclusion. For all measured variables, the largest
improvement was seen during the first year. Both patient
groups had equal amounts of pain over time. ACPA-nega-
tive patients remained more severely fatigued over time (P =
0.002, b = 0.53; this b indicates that on an NRS, ranging
0–10, ACPA-negative patients were 0.5 more severely
fatigued). The self-reported disease activity and the HAQ
were equal between both groups. We corrected for age in all
analyses, and this had a significant effect in only the
longitudinal analysis of the HAQ (b = 0.008, P < 0.001, on a
scale ranging 0–3).
When RA patients fulfilling the 1987 criteria were studied
over time, no statistically significant differences were found
for all variables (see Supplementary Figure 2, available on the
Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23497/abstract). Repeating the an-
alyses in RA patients (both if fulfilling either the 2010 or the
1987 criteria), with additional correction for RF positivity,
SJC66, and symptom duration, resulted in no significant dif-
ferences between ACPA-negative and ACPA-positive patients.
Patient-reported restrictions with work and household
activities at baseline. Baseline characteristics of the 130
ACPA-negative and 152 ACPA-positive patients who com-
pleted questionnaires on work restrictions are presented in
Table 1. Absenteeism and presenteeism among patients
with paid work were not different at disease presentation, as
shown in Table 2. Thirty-eight percent of ACPA-negative
versus 48% of ACPA-positive employed patients reported
absenteeism in the last 3 months (P = 0.30), with median 4
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Figure 1. The percentages of anti–citrullinated protein antibody
(ACPA)–negative (solid line, squares) and ACPA-positive (bro-
ken line, triangles) rheumatoid arthritis patients (fulfilling 2010
criteria) achieving Disease Activity Score remission (<2.4) dur-
ing 4 years of followup.
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Figure 2. Patient-reported outcomes of impairments and limita-
tions of anti–citrullinated protein antibody (ACPA)–negative
(black bars) and ACPA-positive (gray bars) patients fulfilling
the 2010 criteria (A) and the 1987 criteria (B) at baseline. Me-
dian values and corresponding interquartile ranges are shown
for severity of self-reported pain, fatigue, disease activity, and
general well-being, measured by numerical rating scale (NRS),
ranging 0–10, and physical function by the Health Assessment
Questionnaire (HAQ) disability index (DI), ranging 0–3, in the
last 24 hours. * = P < 0.05 by Mann-Whitney U test.
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days missed at work for both groups. Presenteeism due to
arthritis was equal, median 3 versus 5, and the days
worked with restrictions due to arthritis was median 4
versus 3 days for ACPA-negative and ACPA-positive
patients, respectively. Also, restrictions due to arthritis at
home were similar. The median level of restriction was 6
versus 7 in ACPA-negative and ACPA-positive patients, and
median days restrictions due to arthritis was 7 versus 6,
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Figure 3. Patient-reported outcomes of impairments and limitations of anti–citrullinated protein antibody (ACPA)–negative and ACPA-
positive rheumatoid arthritis (RA) patients fulfilling the 2010 criteria during 4 years of followup. Presented are median predicted values
obtained by linear mixed models adjusted for age at inclusion, sex, and year of inclusion. In case of significance of the interaction
between ACPA and time, this was added to the modeled figures. Pain, fatigue, disease activity, and general well-being were measured
by a numerical rating scale (range 0–10). Physical function was measured by the Health Assessment Questionnaire (HAQ) disability
index (range 0–3). Both groups experienced equal pain; ACPA-negative patients were more severely fatigued (P = 0.002, b = 0.53) than
ACPA-positive patients. Both groups had equal self-reported disease activity, general well-being, and HAQ. Following are the numbers
of available data per followup year for ACPA-positive patients for A, pain: 457, 316, 224, 240, 209; B, fatigue: 447, 276, 187, 202, 176;
C, disease activity: 457, 315, 224, 239, 209; D, general well-being: 449, 316, 223, 242, 210; and E, HAQ: 430, 268, 140, 221, 197. Follow-
ing are the numbers of available data per followup year for ACPA-negative patients for pain: 404, 257, 177, 165, 138; fatigue: 400, 232,
150, 143, 114; disease activity: 403, 257, 177, 166, 138; general well-being: 401, 257, 175, 166, 139; and HAQ: 382, 224, 105, 147, 120.
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respectively. Statistically, differences were nonsignificant
for all analyses.
When the RA patients fulfilling the 1987 criteria were
studied, no statistically significant differences were
observed for all analyses (Supplementary Table 5, avail-
able on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23497/abstract).
Course of patient-reported restrictions with work and
household activities during 4 years of disease. Presen-
teeism was assessed during 4 years of followup and was
equal between both groups (P = 0.89). ACPA-negative pa-
tients fulfilling the 2010 criteria had more days with
restrictions at work (P = 0.02, b = 0.89; this b indicates that
ACPA-negative patients had 0.89 days more restrictions)
than ACPA-positive patients. Both restrictions at home (P =
0.17) and the days restrictions at home (P = 0.64) were
equal, as illustrated by Figure 4. Evaluating the RA patients
fulfilling the 1987 criteria over time revealed no significant
differences in all these analyses (Supplementary Figure 3,
available on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23497/abstract).
Results of sensitivity analyses. Because 33% of the
ACPA-negative RA patients fulfilling the 1987 criteria were
RF positive, patients without ACPA or RF (n = 296) were
compared to patients with ACPA and/or RF (n = 646). At
baseline, patients without ACPA and/or RF had more self-
reported pain (P = 0.003), were more severely fatigued (P =
0.045), had a more severe disease activity (P < 0.001), and
more severe functional disability (P = 0.001). General well-
being was equal (P = 0.17). Thus, these findings were
similar to the results of the main analyses. Over 4 years of
followup, patients without ACPA and/or RF had more
severe pain (P = 0.007, b = 0.37), were more severely
fatigued (P = 0.001, b = 0.60), had more severe disease
activity (P = 0.001, b = 0.44), and more severe general well-
being (P = 0.026, b = 0.29). The HAQ over time was not
statistically different between both groups (P = 0.08).
RA patients (fulfilling 2010 criteria) without ACPA or RF
(n = 72) and patients with ACPA and/or RF (n = 210) were
evaluated for restrictions at work and at home. At baseline,
patients with and without ACPA and/or RF had equal absen-
teeism (P = 0.21), presenteeism (P = 0.75), number of days
restrictions at work (P = 0.31), level of restrictions at home
(P = 0.91), and number of days restrictions at home (P = 0.97).
Over 4 years of followup, both groups had equal presen-
teeism (P = 0.78). ACPA- and RF-negative patients had more
days restrictions at work due to arthritis (P = 0.043, b = 1.2).
The level of restrictions at home (P = 0.77) and days restric-
tions at home (P = 0.50) were equal between the groups.
Because DAS-steered treatment became regular as of 2005,
analyses were repeated for RA patients fulfilling the 2010
criteria included during or after 2005. This showed similar
results as that of the total group. At baseline, ACPA-negative
patients reported more severe pain than ACPA-positive
patients (P = 0.016, b = 0.20), more severe fatigue (P = 0.003,
b = 0.45), more severe disease activity (P < 0.001, b = 0.39),
more severe general well-being (P = 0.029, b = 0.14), and
more functional disability (P = 0.001, b = 0.08, on a scale
ranging 0–3). Also, followup data showed similar results as
that of the total group, as shown in Supplementary Figure 4,
available on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23497/abstract.
Finally, to compare the main findings with those obtained
on RA patients that were treated in earlier time periods and
thus with different treatment strategies, the analyses of
patient-reported impairments and limitations in ACPA-
positive and ACPA-negative patients were also performed
on RA patients included in the EAC between 1993 and 1999
Table 2. Baseline data of ACPA-negative and ACPA-positive RA patients (fulfilling 2010 criteria) for restrictions with work
and household activities*
ACPA-negative
(n = 130)
ACPA-positive
(n = 152) P
Productivity at home
Level of restrictions in household work productivity past 7 days, median (IQR) 6 (2–8) 7 (3–8) 0.84
Days restricted in household productivity past 7 days, median (IQR) 7 (3–7) 6 (2–7) 0.25
Employed, no. (%) 40 (31) 69 (45) 0.001
Age, mean  SD years 47  13 49  11 0.31
Type of work 0.48
Physical, no. (%) 7 (18) 16 (23)
Physical and mental no. (%) 19 (48) 25 (36)
Mental, no. (%) 13 (33) 27 (39)
Productivity in the work place†
Work hours per week, median (IQR) 32 (20–38) 28 (20–40) 0.80
Work days per week, median (IQR) 5 (4–5) 5 (3–5) 0.31
Missed any work in last 3 months, no. (%) 15 (38) 33 (48) 0.30
Days missed at work in last 3 months (absenteeism), median (IQR) 4 (2–21) 4 (2–12) 0.92
Level of restrictions in work productivity (presenteeism) past 7 days,
median (IQR)‡
5 (2–8) 3 (2–8) 0.41
Days restricted while at work past 7 days, median (IQR) 4 (2–7) 3 (0–5) 0.20
* ACPA = anti–citrullinated peptide antibody; RA = rheumatoid arthritis; IQR = interquartile range.
† Analyzed in employed patients only.
‡ On a 0–10 scale, where 0 means no restrictions and 10 means complete restrictions.
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(n = 335). As shown in Supplementary Figure 5 (available
on the Arthritis Care & Research web site at http://
onlinelibrary.wiley.com/doi/10.1002/acr.23497/abstract), sev-
eral PROs were more severe in ACPA-positive RA patients
during 4 years of followup; statistical significance was
reached for general well-being (P = 0.020, b = 0.10) and a
tendency toward significance for patient-reported disease
activity (P = 0.06, b = 0.05).
DISCUSSION
This large longitudinal study assessed whether, at present,
ACPA-positive RA patients are still more severely affected
than ACPA-negative RA patients, using self-reported im-
pairments and limitations, including functional disability
and restrictions at work as outcomes. The current availabil-
ity of treatment strategies to suppress inflammation drasti-
cally reduced the frequency and degree of joint damage,
causing the prospects of RA patients to change substantially
(10). Consequently, other disease outcomes have become
central, and patients have rated pain, fatigue, well-being,
and independence, factors which have been studied here,
as most important (14). In addition, physical functioning
and work ability, the key components of independence in
RA, are important from a socioeconomic perspective. We
did not observe a more severe disease patient burden in
ACPA-positive RA. Obviously, the present data require
validation in an independent cohort. Nonetheless, the
assumption that ACPA-positive RA is a more severe disease
seems no longer true in current rheumatology practice
when the mentioned PROs are considered.
Contrary to the hypothesis tested, we actually observed
some differences to the detriment of ACPA-negative pa-
tients. However, these differences were small and clinically
irrelevant. As ACPA-negative patients were older, which
was also shown in previously performed studies, we
corrected for age in all longitudinal analyses (26). Also, when
analyses were additionally adjusted for comorbidities, simi-
lar results were obtained (data not shown). We hypothesized
that the small differences found were most likely caused by
the fact that RA patients without ACPA or RF need >10 joints
involved to fulfill the criteria, and ACPA-negative patients
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Figure 4. Restrictions with work and household activities in anti–citrullinated protein antibody (ACPA)–negative and ACPA-positive
rheumatoid arthritis (RA) patients fulfilling the 2010 criteria. Presented are median predicted values obtained by linear mixed models
adjusted for age at inclusion and sex of ACPA-negative and ACPA-positive RA patients according to the 2010 criteria. A, Presenteeism
(level of restrictions at work), B, number of days restrictions at work, C, level of restrictions, and D, days restrictions with household activi-
ties (at home) over 4 years of followup. Level of restrictions was measured on a scale of 0–10. Days restrictions due to arthritis ranged from
0–7 days. Presenteeism was equal (P = 0.89). ACPA-negative patients had a significantly higher number of days restrictions at work due to
arthritis (P = 0.02, b = 0.89). Level of restrictions (P = 0.17) and number of days they had restrictions at home (P = 0.64) were equal. Follow-
ing are the numbers of available data per followup year for ACPA-positive patients for level of restrictions at work: 63, 52, 44, 31, 19; days
restrictions at work: 53, 50, 36, 27, 17; level of restrictions at home: 103, 83, 75, 59, 37; and days restrictions at home: 89, 69, 63, 51, 28.
Following are the numbers of available data per followup year for ACPA-negative patients for level of restrictions at work: 38, 20, 12, 9, 5;
days restrictions at work: 36, 17, 10, 9, 4; level of restrictions at home: 82, 58, 39, 24, 12; and days restrictions at home: 71, 44, 26, 16, 8.
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with positive RF required 4–10 joints involved, as reflected
by the patient characteristics, which showed that ACPA-
negative RA patients (according to the 2010 criteria) had a
higher TJC and SJC than ACPA-positive patients. This effect
has been observed before (27,28). For this reason we repeated
the analyses in patients classified according to the 1987 crite-
ria, with a more similar joint count between ACPA-negative
and ACPA-positive patients. Then, we did not observe the
somewhat higher disease burden for ACPA-negative RA,
when treated with current treatment strategies and consider-
ing patient-reported impairments and limitations. Thus,
although this study was not set up to compare the 2010 and
1987 criteria, the presented data do confirm previously
reported observations that ACPA-positive RA by the 2010
criteria consists of a less severe subset of patients than
ACPA-positive RA by the 1987 criteria, and that ACPA-
negative RA by the 2010 criteria consists of a more severe
subset of patients compared to ACPA-negative RA by the
1987 criteria (27,28).
In current research, there is a tendency to concentrate
more on ACPA-positive than on ACPA-negative RA. For
example, many more whole genome genetic studies were
performed on ACPA-positive RA (29). This focus in etio-
pathologic studies is possibly explained by the paradigm
that ACPA-negative RA might represent a more heteroge-
neous subset of patients, and that current research has
revealed fewer clues on the possible causes or mediators of
ACPA-negative RA. This could have resulted in ACPA hav-
ing conquered a more prominent position in the identifica-
tion of RA within the 2010 criteria. This study, however,
does not intend to address the issue on the classification cri-
teria. The data presented clearly demonstrate that, at pres-
ent, ACPA-negative RA is equally severe as ACPA-positive
RA when patient-reported impairments and limitations are
studied as outcomes. This has implications for future
research, both for etiopathophysiologic and clinical studies.
The present data highlight the importance of keeping the
scope set on ACPA-negative RA as well, because it has
become an equally severe disease. Moreover, the prevalence
of ACPA-negative RA, as measured in early arthritis cohorts,
concerns up to half of the total RA-population (26,30).
The risk of misdiagnosis is often estimated higher for
ACPA-negative RA than for ACPA-positive RA. In this
study, patients were diagnosed with RA according to the
treating rheumatologist, and this clinical diagnosis was veri-
fied after 1 year of disease in the medical files of all patients.
Hence, patients who developed other diseases were no
longer in the data set. Thereafter, patients were checked as to
whether they fulfilled the 2010 criteria (or 1987 criteria for
subanalyses). When all these conditions were met, patients
were included. Because of this stringent selection, we think
that the risk of misdiagnosis of ACPA-negative RA is low.
Secondary comorbidities like fibromyalgia (FM) could
also influence the PROs, like pain and fatigue (31). Data on
secondary FM were not collected in our cohort. However,
we have no reason to believe that secondary FM would
have influenced our comparisons between autoantibody-
positive and autoantibody-negative patients, as previous
studies have demonstrated that RA patients with and with-
out concomitant FM have an equal prevalence of RF posi-
tivity (31–34).
Measuring patients’ perceptions of health is a standard
approach in observational studies and epidemiologic
research. Measurements of PROs have proven to be valid
and responsive and are sensitive to detect differences
between patient groups (28,35–38). This is the first study to
extensively compare several PROs and work ability among
ACPA-positive and ACPA-negative RA patients during 4
years of followup. Other studies have included the HAQ or
DAS in their analyses and sometimes other PROs (28,36–
39). However, these measurements were mainly performed
at baseline and were not conducted to find differences
between ACPA-positive and -negative patients over time.
Further, it was shown that patients with RA in countries
with higher welfare score worse on PROs, despite lower
levels of objectively measured disease outcomes (8,25,40).
However, this study was conducted in only 1 country.
PROs may be influenced by secular trends (23–25).
Patients studied were included between 2000 and 2014. To
prevent confounding effects, we corrected the analyses for
the year of inclusion. There is no reason to believe that per-
sonal contextual factors such as education or self-efficacy
are different between ACPA-positive and ACPA-negative
patients.
A limitation of PROs could be that reproducibility is
sometimes not very satisfactory (41), and the difficulty of
any study using self-reported outcomes can be that they
may be susceptible to nonresponse and recall bias. We do
not expect this to cause a difference for the comparison
made. Also, we are aware that absenteeism is calculated
with a recall period of 3 months, and some patients present
with symptom durations shorter than this. However, if this
had any effect, it would have led only to an underestima-
tion of absenteeism in ACPA-negative patients, as they
more often had a shorter symptom duration at presentation.
Our frequencies of employment, absenteeism, and presen-
teeism are in accordance with previous studies in RA that
show the considerable interference experienced by RA
patients by means of work restrictions, even despite im-
proved treatment strategies (42–44). Data of the Dutch refer-
ence population were obtained from the Dutch Centraal
Bureau voor Statistiek (45). Here, 45% of the people ages
45–55 years (this was the most prevalent age category in the
patient cohort) had missed days at work due to sickness
during the 12 months of 2016. The average sick leave was 8
days per year. In comparison, 38–48% of the employed
ACPA-negative and ACPA-positive RA patients missed days
at work during a 3-month period. In both ACPA groups the
median days missed at work were 4 per 3 months; extrapo-
lation to a 12-month period would result in an estimated
sick leave of 16 days per year. This is evidently more than
the sick leave in the reference population, and these data
confirm that RA patients currently still have increased work
restrictions. Furthermore, this study adds that no differ-
ences were found between ACPA-positive and ACPA-nega-
tive patients. Notably, the number of working patients was
relatively small in our data set, but findings that the results
on restrictions at work were similar to those of the patient-
reported impairments and limitations show face validity.
This study was conducted to evaluate patients who were
diagnosed early and were treated using up-to-date treat-
ment strategies consisting of early initiation of MTX and
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DAS-steered treatment adjustments. We cannot compare
the actual DMARDs used over time in both groups, as these
data were not collected in a sufficiently accurate manner.
According to local guidelines, initial treatment of ACPA-
positive and ACPA-negative RA was similar: the treatment
regimen consisted of initial treatment with a DMARD
(preferably MTX); in case of failure a second conventional
DMARD was started, and in case of subsequent failure a
biologic DMARD was allowed. From 2005 onward, in our
hospital, DAS-steered treatment became standard (18),
meaning that treatment regimens were adjusted based on
the individual’s disease activity. Analysis of biologic
DMARDs used after 2 years of followup revealed that these
were used by 9% of ACPA-positive patients and 1% of
ACPA-negative patients. Furthermore, the disease activity
measured during followup was similar in both groups.
Hence, it is possible that the ACPA-positive patients
required more, or more aggressive, DMARDs to achieve a
similar DAS. Our results could therefore be considered as
the consequence of improved treatment strategies. In line
with this idea, we evaluated whether PROs were different
between ACPA-positive and ACPA-negative patients who
were treated in earlier periods with treatment strategies that
are now considered outdated. Although the number of
patients in this group was smaller, ACPA-positive patients
indeed had some PROs that were worse than those of
ACPA-negative patients. Results of the present study there-
fore imply that, thanks to improved treatment strategies,
not only have differences between ACPA-positive and
ACPA-negative RA in outcomes, such as joint damage
severity, diminished or disappeared, but that the same can
be seen for differences in PROs.
In conclusion, this study thoroughly compared various
PROs and restrictions with work during followup in ACPA-
positive and ACPA-negative RA patients. The study demon-
strated that ACPA-positive and ACPA-negative RAmanaged
with current treatment strategies represent an equally severe
subset of disease. We do not know if rheumatologists take
PROs into account when making treatment decisions. How-
ever, as joint damage becomes less relevant as an outcome,
in the future we should explore whether PROs can be con-
sidered. Further research is required, but the important per-
sonal health impact, as well as the socioeconomic burden
highlighted by the present study, implies that efforts to fur-
ther improve the disease course should be proportional to
ACPA-positive and ACPA-negative RA.
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